Nanoscope Therapeutics said Chief Executive Officer Sulagna Bhattacharya will deliver a corporate presentation at the H.C. Wainwright Global Investment Conference on September 14, 2026, at 1:00 p.m. ET. The conference runs from September 14 to 16 at the Lotte New York Palace Hotel in New York, and Nanoscope’s management team will hold one-on-one meetings with institutional investors. The biotechnology company is developing MOGENRY (sonpiretigene isteparvovec; MCO-010), an investigational, one-time, in-office intravitreal optogenetic gene therapy for retinal degeneration and vision impairment. Nanoscope said the FDA has accepted and filed its biologics license application for MOGENRY after positive results from the RESTORE Phase 2b/3 trial in retinitis pigmentosa. The company also reported results from the STARLIGHT Phase 2 trial in Stargardt disease and plans to begin a Phase 3 registrational trial in 2026, alongside a planned Phase 2 geographic atrophy program.